Ascletis Pharma, Inc. engages in the research and development, production, marketing, and sale of pharmaceutical products. The company is headquartered in Hangzhou, Zhejiang and currently employs 208 full-time employees. The company went IPO on 2018-08-01. The firm focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The firm's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The firm conducts its business in the domestic and overseas markets.
01672.HK stock price ended at $16.42 on 星期五, after dropping 2.49%
On the latest trading day Feb 13, 2026, the stock price of 01672.HK fell by 2.49%, dropping from $16.80 to $16.42. During the session, the stock saw a volatility of 3.70%, with prices oscillating between a daily low of $16.20 and a high of $16.80. On the latest trading day, the trading volume for 01672.HK decreased by 3.9M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.3M shares were traded, with a market value of approximately $16.1B.